HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorHansoh BioMedical R&D Company
About this trial
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.
Eligibility criteria
Qualifiers
Men or women aged more than or equal to (≥) 18 years.
Histologically or cytologically confirmed, relapsed, locally advanced or metastatic esophageal carcinomas and other advanced solid tumor.
At least one extra measurable lesion according to RECIST 1.1 (cavity structures such as oesophagus cannot serve as measurable lesions).
Agree to provide fresh or archival tumor tissue and blood samples.
Disqualifiers
Subjects with previous or concurrent malignancies
Significant tumor invasion into adjacent organs (aorta or trachea) of esophageal lesions leading to higher risk of bleeding or fistula
Inadequate bone marrow reserve or organ dysfunction.
Evidence of cardiovascular risk
Trial design
Treatments tested in this trial
- HS-20093
Treatment groups
220 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov